Friday, August 16, 2019 2:59:04 PM
I do not see any development to move the stock price up for the remainder of 2019 except a data readout from the safety cohort of prexigebersen plus decitabine. This may happen in a few months based on PN's answer to Chen.
"Well, I think what we would normally do is we will give a readout from the safety in decitabine and prexigebersen that six evaluable patients, as I indicated in my comments, we have five now and three evaluable, two in process. So I’m pretty confident, we will have that sixth one. And when we do that, again we follow the template of what we did when we did our original safety combination with LDAC and prexigebersen. We gave up a readout on the safety, and of course if we had any indications of the efficacy, we also put that out. So if we follow that template, which I'm sure we will, I would expect we have some kind of readout information in the fourth quarter, earlier than later."
This will result only in a short term PPS rise IMO.
The pancreatic treatment BP1003 does even have an IND yet.
"So I'd like to have that IND filed by the end of the first half of 2020, maybe faster. I mean we have the template with BP1002. So we don't have to embed anything new. So it's typically with these things now that on some of these complicated indications, it's the protocol. And we have a lot of reviews as you know, we have a lot of KOLs and they bring new insights. We have one with our solid tumor that came with FDA meetings that gave us some additional direction that we felt we needed to take advantage of and could help speed up things. So that’s the thing. So we should be testing in the in humans in the second half of 2020."
The end of 2020 would be the start of the safety portion of the trial. We are at least 2 1/2 years from evaluable results for the 2nd cohort BPTH1003 .
The Prexigeberson triple drug safety study results (6 patients)will not happen until mid-year 2020 at the earliest and most likely the second half of the year. We will dose two cohorts of 19 patients each in phase II. One for AML and one for MDS. Even an application for FDA acceleration of FDA Status is 2 1/2 years out.
We need 3 1/2 years of cash at a minimum. I expect the PPS to continue the ongoing downward slide. I am only holding 20% of my prior position. I will not consider buying back in unless something big happens or we drop well below $10. That is why I suggest BPTH add 11 million in cash now. In the long run an additional 1 million shares to the float will be meaningless.
Recent BPTH News
- Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Bio-Path Holdings Expands Global Patent Portfolio • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Bio-Path Holdings Provides 2024 Clinical and Operational Update • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:00:34 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/08/2024 10:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 12:10:34 PM
- Bio-Path Holdings Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 12:00:00 PM
- U.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices Dip • IH Market News • 03/08/2024 11:22:25 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:21:27 PM
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 • GlobeNewswire Inc. • 03/01/2024 12:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/29/2024 11:00:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 12:01:09 PM
- Bio-Path Holdings Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:39:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:20:23 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:51:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2024 09:52:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:10:09 PM
- Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/04/2024 10:18:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/22/2023 09:06:16 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:05:23 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM